Switch theme
Sign up to access all valuation multiples
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
2021
2.1K+
LTM Revenue $1.1B
LTM EBITDA $380M
$2.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Embecta has a last 12-month revenue (LTM) of $1.1B and a last 12-month EBITDA of $380M.
In the most recent fiscal year, Embecta achieved revenue of $1.1B and an EBITDA of $193M.
Embecta expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Embecta valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| Gross Profit | $704M | XXX | $735M | XXX | XXX | XXX |
| Gross Margin | 64% | XXX | 65% | XXX | XXX | XXX |
| EBITDA | $380M | XXX | $193M | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 17% | XXX | XXX | XXX |
| EBIT | $320M | XXX | $285M | XXX | XXX | XXX |
| EBIT Margin | 29% | XXX | 25% | XXX | XXX | XXX |
| Net Profit | $105M | XXX | $78.3M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 7% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.3B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Embecta's stock price is $11.
Embecta has current market cap of $615M, and EV of $2.0B.
See Embecta trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.0B | $615M | XXX | XXX | XXX | XXX | $2.71 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Embecta has market cap of $615M and EV of $2.0B.
Embecta's trades at 1.8x EV/Revenue multiple, and 8.1x EV/EBITDA.
Equity research analysts estimate Embecta's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Embecta has a P/E ratio of 5.9x.
See valuation multiples for Embecta and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $615M | XXX | $615M | XXX | XXX | XXX |
| EV (current) | $2.0B | XXX | $2.0B | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | 5.2x | XXX | 8.1x | XXX | XXX | XXX |
| EV/EBIT | 6.1x | XXX | 6.6x | XXX | XXX | XXX |
| EV/Gross Profit | 2.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 5.9x | XXX | 7.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 54.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEmbecta's last 12 month revenue growth is -1%
Embecta's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Embecta's rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Embecta's rule of X is 31% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Embecta and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -1% | XXX | -1% | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Growth | 2% | XXX | 30% | XXX | XXX | XXX |
| Rule of 40 | 19% | XXX | 20% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 31% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Embecta acquired XXX companies to date.
Last acquisition by Embecta was XXXXXXXX, XXXXX XXXXX XXXXXX . Embecta acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Embecta founded? | Embecta was founded in 2021. |
| Where is Embecta headquartered? | Embecta is headquartered in United States of America. |
| How many employees does Embecta have? | As of today, Embecta has 2.1K+ employees. |
| Who is the CEO of Embecta? | Embecta's CEO is Mr. Devdatt Kurdikar, PhD. |
| Is Embecta publicy listed? | Yes, Embecta is a public company listed on NAS. |
| What is the stock symbol of Embecta? | Embecta trades under EMBC ticker. |
| When did Embecta go public? | Embecta went public in 2022. |
| Who are competitors of Embecta? | Similar companies to Embecta include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
| What is the current market cap of Embecta? | Embecta's current market cap is $615M |
| What is the current revenue of Embecta? | Embecta's last 12 months revenue is $1.1B. |
| What is the current revenue growth of Embecta? | Embecta revenue growth (NTM/LTM) is -1%. |
| What is the current EV/Revenue multiple of Embecta? | Current revenue multiple of Embecta is 1.8x. |
| Is Embecta profitable? | Yes, Embecta is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Embecta? | Embecta's last 12 months EBITDA is $380M. |
| What is Embecta's EBITDA margin? | Embecta's last 12 months EBITDA margin is 35%. |
| What is the current EV/EBITDA multiple of Embecta? | Current EBITDA multiple of Embecta is 5.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
